Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

J&J acquires Auris Health for $3.4 billion

Johnson & Johnson plunked down $3.4 billion in cash to acquire privately held Auris Health Inc., a company that has developed robotic endoscopic technologies for the treatment of lung cancer.

Read More »

House Ways and Means Committee Holds Hearing on Drug Prices

The rising costs of prescription medicine took center stage during a hearing held by the Ways and Means Committee in the U.S. House of Representatives.

Read More »

Navitas Life Sciences Announces Acquisition of DataCeutics to Augment Global Clinical Data Science Services

Navitas Life Sciences, a TAKE Solutions Enterprise, announced that the company will acquire Life Sciences services player DataCeutics in North America.

Read More »

Teva Pharmaceutical sees weaker than expected 2019

Teva Pharmaceutical Industries forecast lower revenue and profit for 2019, missing analysts’ expectations, as the company faces generic competition for two key branded drugs.

Read More »

Agenda 2019 Special Feature: Hungry AIs

Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?

Read More »

Top 10 Pipelines To Watch: 2019 Annual Report

The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.

Read More »

Neurogene Launches to Advance Gene Therapies

New York-based Neurogene raised $68.5 million in a Series A funding round to support the company’s pipeline of therapeutics aimed at rare neurological diseases.

Read More »

Indivior loses U.S. district court battle, copycat launches imminent

Generic competitors to British drugmaker Indivior Plc’s blockbuster opioid addiction treatment are on course to launch after the firm’s attempt to stay a U.S. District court judgement was rejected.

Read More »

Gilead misses key goal in NASH liver disease trial, shares sink

Gilead Sciences Inc. said a late-stage study for selonsertib aimed at treating the progressive fatty liver disease NASH failed to meet the key experimental drug’s main goal, sending the company’s shares down 4.6 percent.

Read More »

IFM Therapeutics Launches New Subsidiary Aimed at Parkinson’s and NASH

IFM Therapeutics launched a second subsidiary in less than a year. The Boston-based company launched IFM Due, a subsidiary company developing a suite of cGAS inhibitors and STING antagonists that can target diseases such as NASH, lupus and Parkinson’s.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom